Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-02-01, Stock:NVS, The news for the past five days is as follows:
2021-01-25: NEWS1: Novartis's Earnings Outlook.
2021-01-26: NEWS1: Novartis Slammed: Expects Covid To Impact Drug Sales Until Mid-2021.NEWS2: Novartis Slammed: Expects Covid To Impact Drug Sales Until Mid-2021.NEWS3: The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market.NEWS4: Novartis Gives Cautious Outlook and Warns Covid-19 Impact Will Last Until Mid 2021. The Stock Is Falling..NEWS5: Swiss Miss: Novartis Stock Falls As Novartis Earnings, Sales Fall Short Of Views.NEWS6: Novartis: Q4 Earnings Insights.NEWS7: Merck Just Scrapped Its Coronavirus Vaccines — Is Merck Stock A Buy?.NEWS8: Novartis CEO renews commitment to Sandoz generics unit.NEWS9: Novartis CEO: Hopeful to Accelerate Growth in Second Half.NEWS10: Novartis CEO says U.S. approval timeline for Leqvio 'out of our control'.NEWS11: Novartis's regulatory delays add to pandemic sales hit.NEWS12: Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020..
2021-01-27: NEWS1: Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook.NEWS2: Novartis (NVS) Q4 2020 Earnings Call Transcript.
2021-01-28: NEWS1: A Golden Era of Medicine: Join Mira Life Science Ventures CEO for Fireside Chat Feb. 4.NEWS2: Novartis in Talks to Join Pharma Industry’s Covid Vaccine Push.
2021-01-29: NEWS1: Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis.NEWS2: Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates.

Answer: Decrease